Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1319508 | 0.84 | KMT2A (0.38) | KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL10004688 | 0.84 | GPR84 (0.34) | SMN1; SMN2GPR84 | |
| SCHEMBL13501522 | 0.78 | HCAR2 (0.33) | KMT2A | |
| SCHEMBL2632758 | 0.76 | HTT (0.44) | KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL22655937 | 0.76 | NOS3 (0.38) | KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL29826849 | 0.76 | HTT (0.44) | KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL4288745 | 0.76 | HTT (0.41) | KMT2AKDM4EGPR84 | |
| SCHEMBL22418688 | 0.72 | S1PR2 (0.33) | SMN1; SMN2 | |
| SCHEMBL17495095 | 0.71 | — | — | |
| SCHEMBL20579144 | 0.71 | HRH4 (0.33) | KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| CN-101193868-A | Pyrimidine derivatives for the treatment of GABA B mediated nervous system disorders | NOVARTIS AG (CH) | 2008-06-04 | — | — | CN | disclosed |
| EP-1896428-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS | Novartis AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006136442-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS | NOVARTIS AG (CH) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | DPYD, NUDT1, HPRT1 | KMT2A 2439/4885KDM4E 3418/4885PGK1 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.